DR-261 Chromosomal instability as key regulator of the immune microenvironment of cancers
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-261 Chromosomal instability as key regulator of the immune microenvironment of cancers
Immune cells in the microenvironment of cancers impact disease progression and response to both conventional therapies and immune checkpoint blockers. …
DR-288 The Molecular Profile of Lynch Syndrome-Associated Carcinomas
Patients with Lynch Syndrome (LS) carry a mutation in MLH1, MSH2 (EPCAM), MSH6 or PMS2 and as a result have a genetic predisposition to …
DR-214 Genomic landscape of tumor sensitivity and resistance to anti-cancer drugs in colorectal cancer patients
Colorectal cancer (CRC) ranks as the second most lethal cancer and the third most prevalent malignant tumor worldwide. Despite of …
DR-259 Role of DNA Damage Tolerance Pathways in Genome Maintenance: Linking Mutations to the Lack of DDT
DNA damage response (DDR) network is critical in maintaining genome integrity. The contribution of the DNA damage tolerance (DDT) system …
DR-217 Metastatic breast cancer: can liquid biopsies reliably replace solid biopsies?
There is no cure for metastatic breast cancer, but there are still many treatment options that may prolong life with …
Dr-304 Characterization of genomic alterations in metastatic cutaneous squamous cell carcinoma and basal cell carcinoma
Every year >14,000 patients are diagnosed with cutaneous squamous cell carcinoma (cSCC) and > 35,000 new patients with basal cell …
DR-244 Discovery of mutational signatures associated with chemotherapeutic treatment of cancer
1. Mutational signatures are patterns of mutations that inform us of the mutational process underlying tumorigenesis. We will investigate the mutational …
DR-280 Genomic Correlates of Melanoma Outcomes
Recent advances in melanoma treatments have greatly improved patient survival. However, many patients still do not benefit, and we do …
DR-286 Biomarker discovery using machine learning to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment
Immune checkpoint inhibitors (ICIs) have been approved for treatment of metastatic urothelial cancer patients. Unfortunately, treatment response rates are low …
DR-282 A pan-cancer catalogue of the mutational footprint of DNA repair deficiencies and their potential as biomarkers of treatment efficacy
Cancer develops by the accumulation of mutations in the DNA of individual cells. In many patients, DNA repair mechanisms are …
DR-274 Next generation CUP diagnostics by WGS by improving tumor classification categories and re-training
Cancer of unknown primary (CUP) has a worldwide incidence of 3-5% of all cancers diagnoses. The clinical problem of this …
DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors
The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic …
In ons vak is het heel belangrijk om naast de kennis over de patiënt meer kennis te hebben van de tumor van de patiënt.